Does your drug discovery budget fund novel ideas or data crunching?

Global pharmaceutical R&D spending reached nearly $288 billion in 2024. Yet only 35% of researcher time goes to actual experiments. The rest is absorbed by locating, validating, and reconciling data across disconnected sources. This hidden tax on scientific progress compounds with every new tool, database, and dataset added to the workflow.

This white paper examines the structural data challenges slowing drug discovery organizations today: what they are, where they hit hardest, and how a connected scientific data foundation can redirect researcher time back to the work that advances pipelines.

Read the white paper to understand:

• Why Eroom's Law persists despite advances in high-throughput screening, computational chemistry, and AI
• Three core data challenges driving inefficiency across drug discovery workflows
• How tool fragmentation multiplies the burden on researchers navigating disconnected databases
• What becomes possible when data is curated, harmonized, and connected at the foundation level
• How CAS BioFinder® can help organizations reclaim approximately 180 hours per researcher per year

Download the white paper now and discover how to maintain your competitive advantage.